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ABSTRACT 
TROGLITAZONE SUPPRESSES GLUTAMINE METABOLISM AND TUMOR CELL 
GROWTH THROUGH A PPAR-INDEPENDENT MECHANISM 
 
Miriam R. Reynolds 
November 19, 2014 
In tumor cells, glutamine metabolism provides anaplerotic carbon for the TCA cycle, 
fatty acid synthesis, and precursors for the production of nucleotides and glutathione. 
This metabolic alteration is primarily driven by disruptions in oncogenic or tumor 
suppressor function and results in glutamine dependency for tumor cell survival.  
Troglitazone, a PPARγ agonist, has been reported to alter glutamine metabolism. This 
thesis project addresses whether troglitazone treatment could disrupt glutamine 
metabolism in glutamine-dependent tumor cells.   Results obtained with troglitazone 
treatment include: dose-dependent inhibition of cell proliferation, glutamine uptake, 
glutaminolytic protein expression, steady-state ATP levels, and glutamine carbon flux 
into the TCA cycle.   Silencing PPAR/ activity by using siRNA or a PPARγ antagonist 
did not alter troglitazone’s effects on cell proliferation or glutamine uptake.   
Furthermore, troglitazone treatment caused the suppression of c-Myc protein expression, 
an oncogene known to regulate glutaminolysis.  Thus, troglitazone was shown to disrupt 
tumor glutamine metabolism through a PPAR-independent manner.           
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INTRODUCTION 
 In an effort to understand the mechanism of action of troglitazone as it relates to 
glutamine metabolism and cell growth in cancer cells, I embarked on a research project 
that entailed acquiring an understanding of complex metabolic pathways and 
transcriptional activators involved in metabolic processes. 
 Intermediary metabolism 
 Intermediary metabolism refers to the set of chemical reactions that occur in a 
living organism, specifically within the context of the cell.  Metabolism may be broadly 
divided into two categories:  catabolism, or the breakdown of molecules into components 
resulting in the eventual release of energy, and anabolism, or the synthesis of molecules 
from components requiring the input of energy.  Within cellular metabolism, catabolic 
and anabolic processes are coupled in order to coordinate metabolic pathways and 
maximally conserve energy. 
 Chemical reactions are catalyzed by specialized proteins called enzymes and 
multiple enzymes may be associated with the activation of a given metabolic pathway.  
Regulation of enzymatic activity within a pathway occurs in response to changes within 
the cellular environment or in response to signals received from other cells.  All cells, 
whether prokaryotic or eukaryotic, utilize similar metabolic pathways in order to ensure 
survival.  A central component of cellular metabolism under aerobic conditions involves 
those chemical reactions comprising the tricarboxylic acid (TCA) cycle, an enzymatic 
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 pathway first delineated by Hans  Krebs (Krebs, 1937).  Glucose and glutamine carbons 
may be channeled into the TCA cycle where their respective carbon skeletons serve as 
energetic substrates.     For example, pyruvate derived from glucose may be oxidized 
within the mitochondria to form acetyl-CoA which undergoes a condensation reaction 
with oxaloacetate to form citrate, the first reaction in the TCA cycle.    Similarly, the 
amino acid glutamine may be deamidated to form glutamate followed by a subsequent 
deamination reaction yielding alpha- ketoglutarate (α-KG).   α-KG serves as a central 
intermediate metabolite in the TCA cycle. The oxidation of carbon subunits within the 
TCA cycle yields soluble coenzymes possessing reducing power, coenzymes such           
as dihydronicotinamide adenine dinucleotide (NADH) and reduced flavin adenine 
dinucleotide (FADH2).  These coenzymes are utilized by the electron transport chain 
(ETC) and the associated electron carrier proteins within the mitochondrial membrane to 
generate adenosine triphosphate (ATP) for the cell's use in driving metabolic pathways 
and processes.  Thus, by limiting the flow of carbon subunits into the TCA cycle, co-
factor function and the energetics of a cell may be altered. 
 Regulation of the TCA cycle may occur at the level of substrate availability, 
product inhibition or competitive feedback inhibition.   For each acetyl-CoA molecule 
oxidized to completion within the TCA cycle, 3 NADH, 1 FADH2 and 1 GTP (1 ATP 
equivalent) are generated.  The TCA cycle is turned "on" in response to high ADP/ATP 
or high NAD+/NADH ratios in the cell. The NADH electron carrier molecule is 
generated in the chemical reactions catalyzed by the TCA enzymes isocitrate 
dehydrogenase, alpha- ketoglutarate dehydrogenase and malate dehydrogenase.   The 
NADH produced in these reactions may in turn serve as a negative allosteric regulator of 
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the enzymes citrate synthase, a-ketoglutarate dehydrogenase and isocitrate 
dehydrogenase while ATP may inhibit isocitrate dehydrogenase.   
Glutaminolysis 
 High levels of glutamine utilization have been reported in rapidly dividing cells  
(Newsholme E.A. et al., 1985).  The amino acid  glutamine (GLN) is used for the 
biosynthesis of nucleotides,  glutathione and macromolecules  including proteins and 
lipids  (Newsholme P. et al., 2013).   Even quiescent cells that are not actively 
proliferating have high demands for TCA substrates including glucose and to a lesser 
extent glutamine, presumably for maintaining membrane integrity (Lemon et al., 2010). 
Glutaminolysis refers to the catabolic process within cells whereby the amino acid 
glutamine is partially oxidized within the TCA cycle (McKeehan, 1982).  Glutamine 
carbons may serve as energetic substrates for the TCA cycle, and in addition, may serve 
as a nitrogen sink or repository for excess ammonia which is toxic to cells (Nissim , 
1999).    
 The S-phase of the cell cycle, a period during which a cell doubles its DNA 
content, is dependent upon the presence of glutamine for de novo nucleotide synthesis     
(DeBerardinis et al., 2007).  Glutamine is the substrate for five enzymes involved in the 
de novo synthesis of both purines and pyrimidines with the rate-limiting step of de novo 
purine synthesis being catalyzed by 5'-phosphoribosyl-1-pyrophosphate (PRPP) 
aminotransferase (Cory et al., 2006).  Rates of DNA and protein synthesis in human solid 
tumor cell lines have been shown to be correlated to glutamine concentrations in culture 
media (Wasa et al., 1996).  
3 
  Glutaminolysis requires the activity of glutaminase, an amidohydrolase that 
catalyzes the reaction where glutamine generates glutamate.  Two unique glutaminase 
isoforms have been characterized, GLS1 and GLS2, and each isoform displays tissue 
specificity (Mates et al., 2013).  GLS1, or kidney-type glutaminase, is a phosphate-
dependent isoform expressed in periportal hepatocytes and epithelial cells of renal 
tubules (Mates et al., 2013).    GAC is a splice variant of the kidney-type glutaminase and 
is localized in the mitochondria and associated with tumorigenesis (Cassago et al., 2012).  
GLS2, or liver-type glutaminase, is a phosphate-independent isoform found in 
hepatocytes and within the cellular nuclei of neurons within the central nervous system 
(Mates et al., 2013).               
            Tumor cells that require glutamine for survival may be described as being 
glutamine "addicted" (Wise et al., 2008).       Previous research findings have shown that 
glutamine addicted cells are unable to withstand glutamine deprivation and will undergo 
apoptosis when glutamine is depleted (Yuneva et al., 2007).  The ability of cells to 
synthesize glutamine as opposed to securing the amino acid from extracellular sources 
requires the activity glutamine synthetase.    Reports show that some cancer cell lines 
with β-catenin mutations in Wnt signaling pathway are able to survive glutamine 
deprivation by transcriptional activation of glutamine synthetase, an enzyme that 
catalyzes the amination reaction of glutamate with ammonia to form glutamine (Cadoret  
et al., 2002).  Therefore, mechanisms that may regulate glutaminolysis are of 
considerable interest in cancer biology. 
PPAR nuclear receptors  
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 PPARs, peroxisome proliferation-activated receptors, are nuclear hormone 
receptors that serve as transcriptional activators.    PPARs are bound by ligand, naturally 
occurring or synthetic:  naturally occurring ligands include fatty acids and eicosanoids 
and synthetic ligands include thiazolidinediones for PPARγ and fibrates for PPARα (Lee 
et al., 2003). Once PPARγ has bound ligand, as series of activating events ensue 
including:    releasing of co-repressor molecules,   PPAR dimerizing with the RXR 
receptor activated by its ligand 9-cis retinoic acid, and binding of the PPAR:RXR 
complex to PPAR response elements (PPREs)  within promoters of targeted genes 
followed by  transcriptional activation  (IJpenberg  et al.,1997, Schoonjans et al., 1996).  
Three isotypes of PPARs have been identified:  PPARα, PPARγ and PPARβ/δ and each 
displays tissue specific expression (Lee et al., 2003).   PPARα was the first family 
member to be identified and cloned and was shown to be responsible for peroxisome 
proliferation in liver of rodents animals treated with known hepatocarcinogens as well as 
responsible for the hypolipaedemic effect of the carcinogens (Isseman et al.,1990).   
PPARγ activity is required for adipocyte differentiation and lipid storage while PPARα 
activity is associated with fatty acid oxidation, lipid metabolism, and amino acid 
metabolism (Rakhshandehroo et al., 2010 , Desvergene et al., 1999, Kersten at al., 2001). 
Troglitazone 
  Troglitazone, a synthetic ligand that demonstrates high affinity binding to 
peroxisome proliferation- activated receptor gamma (PPARγ) and to a much lesser extent 
PPARα (Lehmann et al., 1995), was initially used for the treatment of Type II diabetes 
but was removed from the market in 2000 due to reports of idiosyncratic liver toxicity 
(Saha et al., 2010).  Troglitazone is a first-generation thiazolidinedione (TZD) drug  
5 
 (Hauner H., 2002).    Troglitazone reportedly decreases insulin resistance  resulting in 
reduced plasma glucose and insulin levels in Type II diabetic patients via a mechanism 
involving the up-regulation of GLUT1 and GLUT4 glucose transporter proteins in 
skeletal muscle cells and adipocytes (Hauner H., 2002 ) and down-regulating key 
gluconeogenic genes including PEPCK (Davies et sl., 2001).  
   Since troglitazone's removal from the drug market for treatment in Type II 
diabetes patients, researchers have examined a role for troglitazone in the inhibition of 
tumor cell growth and proliferation both in vivo and in vitro (Kubota et al., 1998).                             
Antineoplastic studies using TZDs, specifically troglitazone, have revealed findings 
suggesting that TZDs exert their antitumorigenic properties through both PPAR-
dependent and PPAR-independent mechanisms (Galli et al., 2006).  
  Synthetic PPAR antagonists have been developed for experimental purposes in 
addition to troglitazone and other synthetic agonists.  This category includes GW9662, an 
irreversible suicide inhibitor of PPARγ (Leesnitzer et al., 2002).  Although binding to 
PPARγ with the greatest affinity, GW9662 is capable of binding to PPARα (10 fold less 
affinity) and PPARβ/δ (600 fold less affinity) (Leesnitzer et al., 2002).   
 In addition to the reported effects in skeletal muscles and adipocytes, troglitazone 
has been shown to play a role in modulating glutamine metabolism in different cell types 
(Coates et al., 2002, Routh et al., 2002, Welbourne et al., 2004, Toturro et al., 2004,  
Friday et al., 2011, Oliver et al., 2008 and 2010).  However, the mechanism of action of 
troglitazone on glutamine metabolism has not been thoroughly elucidated, including the 
possible role of PPARs.  In addition, troglitazone has been shown to reduce the levels of  
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c-Myc in prostate cancer cells (Akinyeke et al., 2011) and c-Myc has been shown to play 
a crucial role in glutamine metabolism. 
 c-Myc Oncoprotein 
  The c-Myc oncoprotein serves as a transcription factor and has been 
demonstrated to regulate apoptosis, cell cycle, cell growth and metabolism and 
differentiation (Dang et al., 1999). Overexpression of c-Myc in cultured cells or animal 
transgenic models is associated with a deregulated cell cycle and neoplastic 
transformation (Gabay et al., 2014).   Other oncogenic proteins such as Ras have been 
shown to stabilize the c-Myc protein (Sears et al., 2000).  Downstream effectors of Ras 
signaling including two protein kinases, ERK and GSK3β, are notable candidates for 
phosphorylating c-Myc at key conserved residues including the activating 
phosphorylation event of c-Myc at the serine 62 position within the amino-terminus of 
the c-Myc protein by the predicted ERK kinase which serves to stabilize the protein 
(Sears et al., 2000).    Phosphorylation of c-Myc at the threonine 58 position within the 
amino-terminus of the c-Myc protein by GSK3β serves to destabilize the c-Myc protein 
(Gregory et al., 2003).  The sequential and differential phosphorylation of these key 
conserved sites results in degradation of the c-Myc protein through the proteasome-
ubiquitin pathway (Gregory et al., 2003).  
 Given the described role for c-Myc in neoplastic transformation, researchers have 
focused on elucidating c-Myc's role in regulating tumor cell metabolism (Gabay et al., 
2014).   C-Myc has recently been shown to play a role in regulating key enzymes and 
proteins in the glutaminolytic pathway, namely glutaminase (GLS1) (Gao et al., 2009) 
and the glutamine transporter, ASCT2 (Wise et al., 2008).   By down regulating 
7 
 miR23a/b, a micro RNA that negatively regulates the GLS1 mRNA, c-Myc post-
transcriptionally regulates this key enzyme (Gao et al., 2009).  Upstream of GLS1 
activation, the level of glutamine  transporter expression serves as a control point for the 
glutaminolytic process ( Fuchs et al., 2005).  Glutamine transporters previously shown to 
be up-regulated in human cancer cell lines include the neutral -amino acid transporter 
protein, Slc1A5 (ASCT2) and Slc38A1 (Bode et al., 1995), and c-Myc serves as a 
transcriptional activator for both genes (Wise et al., 2008).   
 In this project, I propose to determine the consequence of troglitazone treatment 
on glutamine metabolism and cell proliferation in glutamine addicted cancer cell types 
and define whether PPAR activity is required for troglitazone's effects.  In addition, I 
seek to examine the role of c-Myc in potentially mediating troglitazone's alteration on 
glutaminolysis in three independent cell types. 
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MATERIALS AND METHODS 
 
Cell culture   
 H460 lung carcinoma and HeLa 229 cervical adenocarcinoma were obtained from 
ATCC and Rb protein family triple knock-out (TKO) MEFs have been previously 
described (Reynolds et al, 2013).   HeLa 299 and TKO MEF cells were cultured in 
DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum 
(Hyclone, Rockford, IL, USA), 25 mM glucose, 4 mM glutamine and 50 μg/ml 
gentamicin sulfate and the H460 cells were cultured in RPMI 1640 (Gibco, Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum (Hyclone, Rockford, IL, USA), 
25 mM glucose, 4 mM glutamine and 50 μg/ml gentamicin sulfate, respectively. Cells 
were maintained at 5% CO2 at 37 °C. 
Glutamine uptake 
 TKO MEF, HeLa 229 and H460 cells were seeded at 8x10
4 
in 6-well plates.  Cells 
were then treated with troglitazone (5-80uM) for 48 hours.  Cells were then washed with 
phosphate-buffered saline and incubated for thirty minutes in glutamine-deficient media.  
Cells were then supplemented with 0.5 uCi [U-
14
C]-glutamine (Perkin Elmer, Waltham, 
MA, USA) for 5 minutes. Medium was aspirated, and cells were washed three times with 
glutamine-free DMEM or glutamine-free RPMI.   Cells were then lysed in 0.1% SDS, 
and sample c.p.m. was acquired on a liquid scintillation counter (Perkin Elmer, Waltham, 
MA, USA).  Counts were normalized to milligram protein as determined by BCA protein 
assay (Pierce, Rockford, IL, USA).  
9 
  Protein expression 
  Protein lysates from troglitazone treated TKO MEF, HeLa 229 and H460 cells 
were resolved by 12% SDS-PAGE electrophoresis, transferred to PVDF membrane, and 
blocked in 5% non-fat dry milk, and 0.1% TBS-Tween 20.  Blots were then probed for 
ASCT2 (Cell Signaling, Danvers, MA, USA), GLS1 (Abnova, Taipei City, Taiwan), c-
MYC (Cell Signaling, Danvers, MA USA), PPAR  (Santa Cruz, Santa Cruz, CA), 
PPARα (Santa Cruz, Santa Cruz, CA), and β-Actin (Pierce, Rockford, IL, USA). Protein 
detection was performed using HRP-conjugated secondary antibodies and ECL Select 
Western Detection Reagent (GE Life Sciences, Piscataway, NJ, USA).   
            Stable isotope resolved metabolomics analysis by NMR 
  H460 cells were seeded at 1 × 10
5
 cells in 6-well plates. H460 cells were then 
treated for 24 hours with different concentrations of troglitazone( 5-80uM) and then for 
an additional 24 hours in the presence of RPMI 1640 supplemented with 25 mM glucose, 
10% dialyzed fetal bovine serum and 4 mM  [13C5,
15
N2]-glutamine (Perkin Elmer, 
Waltham, MA, USA).   Cell pellets were washed three times using phosphate- buffered 
saline, and metabolites were extracted twice with 10% trichloroacetic acid.  2D-TOCSY 
NMR analysis and determination of labeled aspartate incorporation were performed as 
previously described (Reynolds et al., 2013). 
 Cellular steady-state ATP levels 
  Exponentially growing TKO MEF, HeLa 229 and H460 cells were treated with 
different concentrations of troglitazone (5-80uM) for 48 hours. Cells were then lysed in a 
5x passive lysis buffer and ATP concentrations were determined using the ATP 
Determination Kit following manufacturer's protocol (Invitrogen, Carlsbad, CA, USA).   
10 
  
iii 
 
Cellular ATP levels were normalized to milligram protein as determined by BCA protein 
assay (Pierce, Rockford, IL, USA). 
 Cell proliferation 
  To determine glutamine sensitivity, TKO MEF, HeLa 229 and H460 cells were 
seeded at 8x10
4
 in 6-well plates.  At 24 hours post-seeding, media was replaced with 
either complete DMEM containing 10% FBS, 25 mM glucose, 4 mM glutamine and 
50 μg/ml gentamicin sulfate or DMEM without glutamine containing 10% FBS, 25 mM 
glucose, 4 mM glutamine and 50 μg/ml gentamicin sulfate (RPMI 1640 in the case of 
H460 cells). Cell proliferation was assessed as viability using trypan blue exclusion and 
enumeration using a hemocytometer 48 hours after media change.  For troglitazone, 
GW9662 and MG132 experiments, reagents were added 24 hours post- seeding and in the 
case of siRNA experiments, 24 hours post-transfection.  Troglitazone (5-80µM), 
GW9662 (10µM) and MG132 (1mM)   (Cayman Chemicals, Ann Arbor, MI, USA) were 
reconstituted in DMSO. 
 Cell transfections 
  siRNA transfections were performed as previously described (Reynolds et al, 
2013) using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, 
USA)  and  the following siRNAs:   PPARα:  5' -GGAAAGUCCCUUAUCUGAA- 3' 
(Ambion #s72003_Mm) and  PPARα:  5' -GAUCAAGUGACAUUGCUAA- 3' (Ambion 
#s10880_Hs); PPARɣ:  5' - GGGCGAUCUUGACAGGAAA- 3' (Ambion #s72013_Mm) 
and PPARγ:  5' -GACAAAUCACCAUUCGUU- 3' (Ambion #s10886_Hs)  at a final 
concentration of 40 nM.   siRNA species were specific for mouse (TKO MEF) or human  
11 
 (HeLa 229, H460) cell lines.  Cell viability, protein expression and glutamine uptake 
were analyzed at 48 hours post-transfection as described above. 
 Statistics 
  Statistical significance for glutamine uptake, cell viability, steady-state ATP 
production, relative mRNA enrichment and fractional aspartate enrichment was 
determined by a two-sample, nonparametric, two-tailed student t-test.  p < 0.05 was 
considered to be statistically significant. 
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RESULTS 
Mouse embryonic fibroblast deficient for Rb pocket proteins and several tumor 
cancer cell lines are glutamine-dependent  
 To investigate a role for troglitazone in the inhibition of glutaminolysis, we 
identified glutamine-dependent cell lines to be used for further experiments.  Cells were 
plated at a density of 8.0 x 10
4
 in 6-well culture plates and exposed to treatment media for 
24 hours and 48 hours.  Cells were incubated in either complete medium (Glc + Gln) or 
medium depleted of glutamine (Glc-Gln),  and viable cell number was determined using 
trypan blue staining and hemocytometer enumeration.  Removal of glutamine from the 
media resulted in a significant decrease in cell viability in all three cell lines at 24 hours 
and 48 hours (Figure 1).   
Incubation with troglitazone results in the dose-dependent inhibition of glutamine 
uptake 
 To determine troglitazone's effect on glutamine uptake, all three cell lines were 
treated with different concentrations of troglitazone (5uM - 80uM).  After 24 hours and 
48 hours, glutamine uptake was determined using 
14
C-labeled glutamine.    Treatment 
with troglitazone was found to significantly inhibit glutamine uptake in TKO MEF, HeLa 
229 and H460 cells in a dose-responsive manner compared to cells in the vehicle-treated 
control group (Figure 2).    
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Figure 1  - Mouse embryonic fibroblast deficient for  Rb 
pocket   proteins  and  human tumor cancer cell 
lines are glutamine-dependent.   
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Figure 1:   TKO MEF Rb pocket protein-deficient mouse 
embryonic fibroblasts, HeLa 229 human cervical cancer 
cells and H460 non-small cell human lung cancer cells are 
glutamine-dependent. Cells were plated at a density of 8.0 
x 10
4
 in 6-well culture plates and exposed to treatment 
media with or without glutamine for 24 hours and 48 hours. 
Cell proliferation was assessed as viability using trypan 
blue staining and hemocytometer enumeration.    Data is 
presented as the mean ± s.d.  from three independent 
experiments. Statistical significance is reported as  * p < 
0.05. 
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Figure 2  - Incubation with troglitazone results in the dose-
dependent inhibition of glutamine uptake. 
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Figure 2:    PPARγ agonist troglitazone inhibits  glutamine 
uptake in TKO MEF, HeLa 229 and H460 cells.  Cells were 
plated at a density of 8.0 x 10
4
 in 6-well culture plates and 
exposed to different concentrations of troglitazone for 24 
hours and 48 hours. Glutamine uptake was determined 
using 
14
C- labeled glutamine.  Data is presented as percent 
of vehicle and shown as the mean ± s.d. from three 
independent experiments. Statistical significance is reported 
as * p < 0.05.  
17 
 Incubation with troglitazone results in the dose-dependent suppression of 
glutaminolytic proteins 
 Both ASCT2 and GLS1 have been demonstrated to be overexpressed in cancer 
cell lines and expression of these proteins is directly correlated with glutamine utilization 
in tumor cells.  To determine if these glutaminolytic proteins may be contributing to the 
reduction in glutamine uptake, we examined ASCT2 and GLS1 expression in cells 
treated with different concentrations of troglitazone (5uM-80uM).   Treatment with 
troglitazone was found to significantly suppress the expression of glutaminolytic 
proteins, ASCT2 and GLS1, in TKO MEF, HeLa 229 and H460 cells in a dose-
responsive manner (Figure 3).   
Incubation with troglitazone results in the dose-dependent suppression of steady-
state ATP levels 
 Glutamine can supplement ATP production through TCA cycle anaplerosis.  To 
examine whether diminished glutamine uptake in response to treatment would affect ATP 
levels, cells were incubated with different concentrations of troglitazone (5uM - 80uM).  
After 48 hours, cells were lysed and cellular ATP levels were determined using a firefly 
luciferase/luciferin bioluminescence assay.  A significant dose-dependent decrease in 
steady-state ATP levels was observed at 40uM in all three cell lines (Figure 4).   
Although other metabolic processes may affect ATP levels within the cell, the decrease in 
ATP levels in these cell lines correlates with dose-dependent decreases in glutamine 
uptake (Figure 2). 
Incubation with troglitazone results in reduced incorporation of glutamine carbon 
into the TCA cycle  
18 
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Figure 3 - Incubation with troglitazone results in the dose-
dependent suppression of glutaminolytic  proteins.  
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Figure 3:   PPARγ agonist troglitazone suppresses 
glutaminolytic enzymes in  TKO MEF, HeLa 229 and  
H460 cells. Cell lysates were obtained 48 hours after 
treatment with different concentrations of troglitazone 
ranging from 5uM-80uM.   Protein expression for GLS1, 
ASCT2 and β-Actin were determined by Western blot 
analysis. Blots reveal a dose-dependent inhibition on levels 
of expression of glutaminolytic proteins, GLS1 and 
ASCT2, in response to troglitazone treatment in all three 
cell lines. 
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Figure 4 - Incubation with troglitazone results in the dose-
dependent suppression of steady-state ATP 
levels.        
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Figure 4:    PPARγ agonist troglitazone suppresses steady-
state ATP levels in TKO MEF, HeLa and H460 cells.  Cells 
were plated at a density of 8.0 x 10
4
 in 6-well culture plates 
and exposed to treatment media for 48 hours.   ATP levels 
were determined using a luciferase reporter kit. Data is 
presented as relative ATP concentration where vehicle is 
1.0, and shown as the mean ± s.d. from three independent 
experiments. Statistical significance is reported as * p < 
0.05. 
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To directly examine downstream glutamine metabolism, 2D-TOCSY NMR analysis 
using 
13
C - labeled glutamine was employed to establish whether reduced glutamine 
uptake results in the concomitant reduction of glutamine anaplerosis into the TCA cycle.  
Glutamine carbons enter the TCA cycle after deamidation to glutamate followed by 
conversion to alpha-ketoglutarate.  The H460 cell line was incubated with different 
concentrations of troglitazone (5uM-80uM).  At 24 hours, cells were labeled with 
13
C -
glutamine for an additional 24 hours.  Troglitazone treatment resulted in a significant 
dose-dependent decrease in labeled glutamine-derived carbon incorporation into aspartate 
which is directly labeled from the TCA cycle intermediate oxaloacetate (Figure 5 A-B). 
Incubation with troglitazone results in the dose-dependent inhibition of cell 
proliferation 
 To determine effects on cell proliferation, all three cell lines were treated with 
different concentrations of troglitazone (5uM - 80uM).  After 24 hours and 48 hours, cell 
proliferation was assessed as viability using trypan blue staining and hemocytometer 
enumeration.  Treatment with troglitazone was found to inhibit cell proliferation in a 
dose-responsive manner in TKO MEF, HeLa 229 and H460 cells at 24 hours and 48 
hours (Figure 6).   
 Incubation with siRNAs directed against PPARα and PPARγ results in the   
suppression of PPARα and PPARγ protein expression 
 To determine what role PPARs may be playing in troglitazone's effects on  
glutaminolysis and cell proliferation,  I  knocked down expression of PPARγ and PPARα 
using siRNA species directed against these targets (Figure 7).  Western blot analysis  
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Figure 5A-B:  Incubation with troglitazone results in the 
reduced incorporation of glutamine carbons into the TCA 
cycle in H460 cells.   Incorporation of glutamine carbon into 
aspartate was determined by stable isotope labeling with 
[
13
C
5
, 
15
N
2
]-glutamine.    Cells were treated with different 
concentrations of  troglitazone for 48 hours.   (A) Shown are 
the 2-D NMR spectra of TOSCY cross-peaks corresponding 
to aspartate C2-C3 and 
13
C satellites. The pattern indicates a 
mixture of fully labeled aspartate via the first turn of the 
Krebs cycle, and aspartate that shows the second turn of the 
Krebs cycle after condensation of OAA with unlabeled 
acetyl CoA from unlabeled glucose.  The boxes connect the 
13
C satellite peaks of aspartate, consistent with the direct 
production of aspartate from glutamine.  The central peak 
denoted 
12
C is from aspartate that contains no 
13
C. (B)  
Graphical representation of the fraction of 
13
C-aspartate to 
12
C-aspartate shows a dose-dependent decrease with 
increasing concentrations of troglitazone.  Data are 
represented as relative incorporation where 
12
C of 
13
C is 
100.  Statistical significance is reported as * p < 0.05.  
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Figure 6  -  Incubation with troglitazone results in  the dose-  
dependent inhibition of cell proliferation.  
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Figure 6:   PPARγ agonist troglitazone inhibits cell 
proliferation in TKO MEF, HeLa 229 and H460 cells. Cells 
were plated at a density of 8.0 x 10
4
 in 6-well culture plates 
and exposed to different concentrations of troglitazone for 
24 hours and 48 hours. Cell proliferation was assessed as 
viability using trypan blue staining and hemocytometer 
enumeration.    Data is presented as percent of vehicle and 
shown as the mean ± s.d. from three independent 
experiments. Statistical significance is reported as * p < 
0.05. 
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Figure 7A-B -  Incubation with siRNAs directed against   
  PPARα   and PPARγ results in the suppression        
  of  PPARα and PPARγ protein expression. 
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Figure 7A-B:  Incubation with siRNAs directed against 
PPARγ and PPARα results in the suppression of PPARγ 
and PPARα protein expression.  TKO MEF, HeLa 229 and 
H460 cells were transfected with siRNAs directed against 
PPARα (A) and PPARγ (B) and protein expression for 
PPARα and PPARγ and β-Actin were determined by 
Western blot analysis. 
29 
 revealed that expression of both PPARγ (Figure 7B) and PPARα (Figure 7A) were 
greatly diminished 48 hours post-transfection.   
Incubation with siRNA directed against PPARγ in the presence of troglitazone fails 
to rescue glutamine uptake  
 Cells were transfected with siRNA directed against PPARγ (Figure 7B) and then 
treated with different concentrations of troglitazone (5uM - 80uM).  After 48 hours, 
glutamine uptake was determined using 
14
C -labeled glutamine.   Knockdown of PPARγ 
in the presence of troglitazone failed to result in a significant rescue of glutamine uptake 
within any of the three cell lines (Figure 8).   
Incubation with siRNA directed against PPARγ in the presence of troglitazone fails 
to rescue cell proliferation  
 Cells were transfected with siRNA directed against PPARγ (Figure 7B) and then 
treated with different concentrations of troglitazone (5uM - 80uM).  After 48 hours, cell 
proliferation was assessed as viability using trypan blue staining and hemocytometer 
enumeration.  Knockdown of PPARγ in the presence of troglitazone failed to result in a 
significant rescue of cell proliferation within any of the three cell lines (Figure 9).   
Incubation with siRNA directed against PPARα in the presence of troglitazone fails 
to rescue glutamine uptake 
 Cells were transfected with siRNA directed against PPARα (Figure 7A) and then 
treated with different concentrations of troglitazone (5uM - 80uM).  After 48 hours, 
glutamine uptake was determined using 
14
C -labeled glutamine.  Knockdown of PPARα 
in the presence of troglitazone failed to result in a significant rescue of glutamine uptake 
within any of the three cell lines (Figure 10).    
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Figure 8 -  Incubation with siRNA directed against PPARγ  
in the presence of troglitazone fails to rescue  
glutamine uptake.  
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Figure 8:   Incubation with troglitazone and siRNA 
directed against PPARγ fails to rescue  glutamine uptake in 
TKO MEF, HeLa 229 and H460 cells.  Cells were plated at 
a density of 8.0 x 10
4
 in 6-well culture plates and exposed 
to different concentrations of troglitazone with or without 
siRNA for  48 hours.   Glutamine uptake was determined 
using 
14
C- labeled glutamine.  Data is presented as percent 
of vehicle and shown as the mean ± s.d. from three 
independent experiments. Statistical significance is 
reported as  * p < 0.05.  
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Figure 9 - Incubation with siRNA directed against PPARγ  
in the presence of troglitazone fails to  rescue cell 
proliferation. 
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Figure 9:   Incubation with troglitazone and siRNA directed 
against PPARγ fails to  rescue  cell proliferation in TKO 
MEF, HeLa 229 and H460 cells.  Cells were plated at a 
density of 8.0 x 10
4
 in 6-well culture plates and exposed to 
different concentrations of troglitazone with or without 
siRNA for  48 hours.  Cell proliferation was assessed as 
viability using trypan blue staining and hemocytometer 
enumeration.    Data is presented as percent of vehicle and 
shown as the mean ± s.d. from three independent 
experiments. Statistical significance is reported as * p < 
0.05. 
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Figure 10 -  Incubation with siRNA directed against 
PPARα in the presence of troglitazone fails    
to rescue glutamine uptake.  
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Figure 10:    Incubation with troglitazone and siRNA 
directed against PPARα fails to  rescue glutamine uptake in 
TKO MEF, HeLa 229 and H460 cells.  Cells were plated at 
a density of 8.0 x 10
4
 in 6-well culture plates and exposed to 
different concentrations of troglitazone with or without 
siRNA for 48 hours. Glutamine uptake was determined 
using 
14
C- labeled glutamine.  Data is presented as percent 
of vehicle and shown as the mean ± s.d. from three 
independent experiments. Statistical significance is reported 
as  * p < 0.05.  
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Incubation with siRNA directed against PPARα in the presence of troglitazone fails 
to rescue cell proliferation  
 Cells were transfected with siRNA directed against PPARα (Figure 7A) and then 
treated with increasing concentrations of troglitazone (5uM-80uM).  After 48 hours, cell 
proliferation was assessed as viability using trypan blue staining and hemocytometer 
enumeration. Knockdown of PPARα failed to demonstrate a significant rescue of cell 
proliferation (Figure 11).  
Incubation with PPARγ antagonist, GW9662, in the presence of troglitazone fails to  
rescue glutamine uptake 
 Cells were treated with GW9662, a PPARγ antagonist, at a concentration of 10uM 
and in the presence of increasing concentrations of troglitazone (5uM-80uM).  After 48 
hours, glutamine uptake was determined using 
14
C-labeled glutamine.  Inhibition of 
PPARγ by GW9662 failed to demonstrate a significant rescue of glutamine uptake within 
any of the three cell lines (Figure 12).   
Incubation with PPARγ antagonist, GW9662, in the presence of troglitazone fails to  
rescue cell proliferation  
 Cells were treated with GW9662, a PPARγ antagonist, at a concentration of 10uM 
and in the presence of increasing concentrations of troglitazone (5uM-80uM).  After 48 
hours, cell proliferation was assessed by viability using trypan blue staining and 
hemocytometer enumeration.  Inhibition of  PPARγ by GW9662 failed to demonstrate a 
significant rescue of cell proliferation within any of the three cell lines (Figure 13).   
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Figure 11 -  Incubation with siRNA directed against PPARα 
in the presence  of troglitazone fails to  rescue   
cell proliferation.   
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Figure 11:     Incubation with troglitazone and siRNA 
directed against PPARα fails to rescue  cell proliferation in 
TKO MEF, HeLa 229 and H460 cells.  Cells were plated at 
a density of 8.0 x 10
4
 in 6-well culture plates and exposed 
to different concentrations of troglitazone with or without 
siRNA for  48 hours. Cell proliferation was assessed as 
viability using trypan blue staining and hemocytometer 
enumeration.    Data is presented as percent of vehicle and 
shown as the mean ± s.d. from three independent 
experiments. Statistical significance is reported as  * p < 
0.05. 
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Figure 12 - Incubation with PPARγ antagonist, GW9662,  in 
the presence of troglitazone fails to  rescue  
glutamine uptake.  
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Figure 12:   Incubation with troglitazone and PPARγ 
antagonist, GW9662, fails to rescue  glutamine uptake in 
TKO MEF, HeLa 229 and H460 cells. Cells were plated at 
a density of 8.0 x 10
4
 in 6-well culture plates and exposed 
to different concentrations of troglitazone with or without 
GW9662 for 48 hours.  After 48 hours, glutamine uptake 
was determined using 
14
C-labeled glutamine.    Data is 
presented as percent of vehicle and shown as the mean ± 
s.d. from three independent experiments. Statistical 
significance is reported as * p < 0.05. 
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Figure 13 -  Incubation with PPARγ antagonist, GW9662,  
in the presence of  troglitazone fails to  rescue  
cell proliferation.  
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Figure 13:   Incubation with troglitazone and PPARγ 
antagonist, GW9662,  fails to  rescue  proliferation in TKO 
MEF, HeLa and H460 cells.  Cells were plated at a density 
of 8.0 x 10
4
 in 6-well culture plates and exposed to 
different concentrations of troglitazone with or without 
GW9662 for 48 hours. Cell proliferation was assessed as 
viability using trypan blue staining and hemocytometer 
enumeration.    Data is presented as percent of vehicle and 
shown as the mean ± s.d. from three independent 
experiments. Statistical significance is reported as  * p < 
0.05. 
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 Incubation with troglitazone results in the suppression of c-Myc protein expression  
 Given previous reports demonstrating a role for c-Myc in regulating 
glutaminolysis through direct or indirect control of both ASCT2 and GLS1, I investigated 
whether troglitazone would affect c-Myc expression.  Cell extracts were obtained 48 
hours after incubation using concentrations of 5uM-80uM of troglitazone.   Protein 
expression for c-Myc was determined by Western blot using anti-c-Myc antibody, and a 
dose-dependent inhibition was observed in all three cell lines (Figure 14). 
Incubation with proteasomal inhibitor, MG132, in the presence of troglitazone 
rescues expression of the c-Myc protein 
 To determine whether the decrease in c-Myc levels is proteasomal mediated, 
H460 cell extracts were obtained 24 hours after troglitazone incubation using 
concentrations 5uM-80uM in the presence or absence of the proteasome inhibitor, 
MG132 (1mM).   Protein expression for c-Myc was determined by Western blot using 
anti-c-Myc antibody, and co-treatment with MG132 was able to rescue c-Myc expression 
in H460 cells (Figure 15).                                                                                                                                                                                                                               
Incubation with proteasomal inhibitor, MG132, in the presence of troglitazone 
results in the partial rescue of cell proliferation and glutamine uptake 
 To examine whether this rescue phenotype extends to glutamine uptake and cell 
proliferation, H460 cells were treated with different concentrations of troglitazone (5uM-
80uM) with or without the proteasome inhibitor MG132 (1mM).  Co-treatment with 
MG132in the presence of troglitazone results in a partial rescue of cell proliferation 
(Figure 16A).  After 24 hours, glutamine uptake was determined using 
14
C -labeled   
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Figure 14 - Incubation with troglitazone results in the 
suppression  of  c-Myc protein expression. 
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Figure 14:   Incubation with troglitazone results in the 
suppression  of c-Myc protein expression in TKO MEF,   
HeLa 229 and H460 cells. Cell lysates were obtained 48 
hours after treatment with different concentrations of 
troglitazone.   Protein expression for c-Myc and β-Actin 
were determined by  Western blot analysis. Blots reveal a 
dose-dependent inhibition on levels of expression of c-Myc 
in response to troglitazone treatment in all three cell lines. 
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Figure 15 - Incubation with proteasomal inhibitor, MG132,  
in the presence of troglitazone results in the  
rescue of c-Myc protein expression. 
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  β-Actin  
 c-MYC 
H460 
1.00         0.92        0.80       0.53        0.30      
1.00        1.40       0.99         1.00      1.20  
47 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15:  Incubation with MG132 in the presence of 
troglitazone prevents proteasomal degradation of the c-
Myc protein at 24 hours.  Protein expression for c-Myc 
protein and β-actin in H460 cells in response to different 
concentrations of troglitazone at 24 hours with or without 
the proteasome inhibitor, MG132, was determined by 
Western blot analysis.  Shown is a representative image 
from two separate experiments.  Rescue of the expression 
of the c-Myc protein  was observed in response to 
troglitazone treatment with MG132 in the H460 cells. 
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Figure 16  A-B - Incubation with proteasomal inhibitor, 
MG132, in the presence of troglitazone 
results in the partial rescue of cell 
proliferation and glutamine uptake. 
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Figure 16 A-B:  Incubation with MG132 in the presence of 
troglitazone in the H460 cells  at 24 hours provides a partial 
rescue of cell proliferation and glutamine uptake.  (A) After 
24 hours of troglitazone treatment with or without MG132, 
cell proliferation in the H460 cells was assessed by 
counting viable cell number using trypan blue staining and 
hemocytometer enumeration.   A partial rescue of cell 
proliferation with MG132 was observed at 20uM and 
40uM.  Data are represented as percent of vehicle.  Mean + 
s.d. from three independent experiments.  Statistical 
significance is reported as * p < 0.05.  (B) After 24 hours of 
troglitazone treatment with or without MG132, glutamine 
uptake in the H460 cells was assayed by 
14
C-glutamine 
labeling.  A partial rescue of glutamine uptake with MG132 
was observed at 20 uM and 40uM.  Data are represented as 
percent of vehicle.  Mean + s.d. from three independent 
experiments.   Statistical significance is reported as * p < 
0.05.  
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glutamine, and co-treatment with MG132 in the presence of troglitazone results in a 
partial rescue of glutamine uptake (Figure 16B).   
Incubation with proteasomal inhibitor, MG132, in the presence of troglitazone 
results in the partial rescue of glutaminolytic protein expression 
 Since MG132 was able to rescue c-Myc expression, I determined whether MG132 
also rescued expression of c-Myc downstream targets, ASCT2 and GLS1.  H460 cell 
extracts were obtained 24 hours after troglitazone incubation using concentrations 5uM-
80uM in the presence or absence of the proteasome inhibitor, MG132 (1mM).  Protein 
expression for ASCT2 and GLS1 was determined by Western blot, and co-treatment with 
MG132 was able to substantially rescue ASCT2 and GLS1 expression in H460 cells  
(Figure 17). 
Overexpression of mutant c-Myc protein in the presence of troglitazone fails to 
rescue cell proliferation and glutamine uptake 
 Mutation of T58A in c-Myc has been reported to suppress proteasomal 
degradation.  To determine if overexpression of the c-Myc mutant is able to rescue 
cellular processes from troglitazone treatment, H460 cells that stably express Sham or 
T58A mutant c-Myc were treated with different concentrations of troglitazone (5uM-
80uM).   After 48 hours, cell lysates were obtained, and protein expression for c-Myc was 
determined by Western blot using anti-c-Myc antibody.   Overexpression of T58A mutant 
c-Myc was unable to rescue c-Myc expression in H460 cells  (Figure 18A).  In these 
same cells, after 48 hours, cell proliferation was assessed as viability using trypan blue 
staining and hemocytometer enumeration.  Overexpression of T58A mutant c-Myc in the 
presence of troglitazone fails to result in the rescue of cell proliferation (Figure 18B).    
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Figure 17 - Incubation with proteasomal inhibitor,  MG132,      
in the presence of troglitazone results in the partial 
rescue of glutaminolytic protein expression. 
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Figure 17:   Incubation with MG132 in the presence of 
troglitazone results in the partial rescue of expression of the 
glutaminolytic proteins, ASCT2 and GLS1.  Protein 
expression for ASCT2, GLS1 and β-actin in H460 cells in 
response to different concentrations of troglitazone at 24 
hours with or without the proteasome inhibitor, MG132, was 
determined by Western blot analysis.  Shown is a 
representative image from two separate experiments.  Partial 
rescue of the expression of the glutaminolytic proteins, 
ASCT2 and GLS1,  was observed in response to troglitazone 
treatment with MG132 in the H460 cells. 
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Figure 18  A-C - Overexpression of  the T58A mutant c-Myc 
in the presence of troglitazone fails to 
rescue cell proliferation or glutamine 
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Figure 18 A-C:    Overexpression of  the T58A mutant c-
Myc in the presence of troglitazone fails to rescue cell 
proliferation or glutamine uptake.  (A) Protein expression 
for c-Myc and β-actin in H460 cells stably transfected with 
Sham or T58A mutant c-Myc in response to different 
concentrations of troglitazone at 48 hours was determined 
by Western blot analysis.  Shown is a representative image 
from two separate experiments.  Partial rescue of the 
expression of the c-Myc protein at 40uM troglitazone was 
observed in the presence of T58A mutant c-Myc.  (B) In 
these same cells, after 48 hours of troglitazone treatment, 
cell proliferation was assessed by counting viable cell 
number using trypan blue staining and hemocytometer 
enumeration.  No rescue of cell proliferation with T58A 
mutant c-Myc was observed.  Data are represented as 
percent of vehicle.  Mean + s.d. from three independent 
experiments.   (C)  In these same cells, after 48 hours of 
troglitazone treatment, glutamine uptake was assayed by 
14
C-glutamine labeling.  No rescue of glutamine uptake 
with T58A mutant c-Myc was observed.  Data are 
represented as percent of vehicle.  Mean + s.d. from three 
independent experiments.  
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 Lastly, after 48 hours, glutamine uptake was determined using 
14
C -labeled glutamine,  
and overexpression of T58A mutant c-Myc in  the presence of troglitazone also fails to 
rescue  glutamine uptake (Figure 18C).  
Incubation with troglitazone and metformin results in a synergistic inhibition of cell 
proliferation  
 To examine whether troglitazone's inhibitory effect on cell proliferation could be 
augmented, we combined troglitazone with another therapeutic drug, metformin, which 
has been previously shown to sensitize cells to glutamine disruption.    After 48 hour and 
72 hour incubation with either troglitazone (10uM) or metformin (1mM), or a 
combination of troglitazone (10uM) plus metformin (1mM), cell proliferation was 
assessed as viability using trypan blue staining and hemocytometer enumeration.  A 
statistically significant and synergistic inhibitory effect was observed for the combination 
troglitazone plus metformin treatment  for both HeLa 229 cells at 48 hours and H460 
cells at 48 hours and 72 hours (Figure 19).        
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Figure 19 - Incubation with troglitazone and metformin 
results in an additive inhibitory effect on cell 
viability. 
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Figure 19:  H460 and HeLa 229 cells were incubated with 
10uM troglitazone or 1mM metformin or  10uM 
troglitazone with 1mM metformin for 48 hours and 72 
hours.  Cell proliferation in the cells was assessed by 
counting viable cell number using trypan blue staining and 
hemocytometer enumeration .  Data are represented as 
percent of vehicle.  Mean + s.d. from three independent 
experiments.  Statistical significance is represented as  * p 
< 0.05.   H460 cells at 48 hours and 72 hours showed 
statistically significant and synergistic inhibition of cell 
proliferation with the combinatorial troglitazone and 
metformin treatment while the HeLa 229 cells at 48 hours 
showed statistically significant and synergistic inhibition 
of cell proliferation with the combinatorial troglitazone and 
metformin treatment. 
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DISCUSSION 
 The goal of this research project was to determine the mechanism by which 
troglitazone regulates glutamine metabolism and cell proliferation in select neoplastic cell 
types. 
Troglitazone inhibits glutaminolysis 
 I began this project by examining the effects of troglitazone on three cell lines 
deemed to be dependent on glutamine for survival, TKO MEF, HeLa 229, and H460 
(Figure 1).  Troglitazone, a previously FDA approved drug for the treatment of Type II 
diabetes, has been shown to possess anti-tumorigenic properties (Colmers et al., 2012).   I 
have shown through a series of experiments that troglitazone treatment in  glutamine-
dependent cell lines resulted in diminished glutaminolysis as evidenced by the inhibited 
expression of key glutaminolytic proteins, GLS1 and ASCT2 (Figure 3),   glutamine 
uptake (Figure 2) and reduced steady-state ATP levels (Figure 4).  Using the H460 cell 
line, glutamine carbon flux into the TCA cycle as measured by  NMR analysis using 
13
C-
labeled glutamine was shown to be suppressed with increased troglitazone concentrations 
(Figure 5A-B).  In addition, diminished glutaminolysis was accompanied by a 
concomitant inhibition of cell proliferation (Figure 6). 
 Robust inhibition of the glutamine transporter, ASCT2, was evident at 40uM 
troglitazone in all three cell lines at 48 hours (Figure 3).  Corresponding values reported 
for glutamine uptake were approximately 60% to 70% of those values reported for   
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 respective controls (Figure 2) suggesting that alternative glutamine transporters are 
active.  The expression of the Slc38A2 (SNAT2), a sodium-coupled neutral amino acid 
transporter, has been shown to be regulated transcriptionally by activating protein 
complexes bound to amino acid response elements within the SNAT2 promoter during 
amino acid starvation (Palii et al., 2006). HeLa cells have been shown to be able to up-
regulate SNAT2 in response to amino acid deprivation (Gaccioli et al., 2006).   
 Previously, researchers have shown that troglitazone is capable of modulating 
glutamine metabolism by generating cellular acidosis which in turn regulates  anaplerosis 
via the driving of glutamate flux  through glutamate dehydrogenase (GDH), a pH- 
dependent enzyme located within the mitochondrial matrix, as opposed to the routing  of 
glutamate  through  alanine aminotransferase (ALT)  (Coates et al., 2002, Routh et al., 
2002, Welbourne et al., 2004, Toturro et al., 2004,  Friday et al., 2011, Oliver et al., 2008 
and 2010). Troglitazone's effect on modulating glutamate flux occurs in response to 
troglitazone's ability to inhibit the sodium-dependent proton exchanger, NHE1, thus 
preventing extrusion of protons into the extracellular space, causing the shift towards a 
more acidic cytosolic pHi (Coates et al., 2002, Routh et al., 2002, Welbourne et al., 2004, 
Toturro et al., 2004, Friday et al., 2011, Oliver et al., 2008 and 2010).   This cytosolic 
acidification favors the activation of GDH which is a pH sensitive enzyme (Moreadith et 
al., 1984).    The deamination reaction of glutamate by GDH produces alpha- 
ketoglutarate (a-KG), an intermediary metabolite for the TCA cycle, which, in turn, 
enhances the production of GTP.  Ultimately, the GTP produced serves as a potent 
allosteric inhibitor of GDH (Fang et al., 2002).  A role for the NHE1 in cancer 
development and progression has been a topic of debate for years (Reshken et al., 2000).    
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Researchers looking at growth factor signaling and breast cancer cell growth in the MCF-
7 cell line showed that troglitazone's inhibitory effect on breast cancer cell growth as it 
relates to DNA synthesis was associated with NHE1 inhibition and cellular acidosis and 
not disruption of the growth factor signaling pathway (Friday et al., 2011)  
   Flux away from ALT and towards GDH may be associated with a reduction in 
pyruvate levels as well as a reduction in cytosolic pH.  Pyruvate levels diminished as a 
result of reduced glycolysis and enhanced flux of glutamine through the GDH pathway 
into the TCA cycle has been documented to occur in various tumor cell lines (Yang et al., 
2009).  A  role for the oncoprotein c-Myc within this metabolic profile may be evident 
since c-Myc has been shown to transcriptionally regulate many proteins involved in 
glycolysis including hexokinase II (HK2) and  the glucose transporter GLUT1 (Dang  et 
al., 2009).    In the SNB-19 glioma cell line, binding of the predominant hexokinase 
isoform to mitochondrial membranes is enhanced under alkaline cytosolic pH (Miccoli et 
al., 1996)   and hexokinase association with the mitochondrial membrane has long been 
argued to be a primary marker for a tumorigenic phenotype (Ros et al., 2013, Nakashima 
et al., 1986, Pederson et al., 2002).  Troglitazone treatment resulting in altered cytosolic 
pH through NHE1 inhibition may be suppressing hexokinase association with the 
mitochondrial membrane. 
  C-Myc has been shown to regulate the expression of GLS1 and ASCT2 (Yuneva 
et al., 2007, Wise et al. 2008), thus I examined c-Myc expression in the glutamine-
dependent cell lines in response to troglitazone treatment.  In previous reports, 
researchers using prostate cancer cell lines showed that troglitazone treatment resulted in 
reduced c-Myc expression (Akinyeke et al., 2011).  Expectedly, I observed that   
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 troglitazone treatment resulted in diminished expression of c-Myc protein in the three cell 
lines (Figure 14).  When H460 cells were treated with troglitazone in the presence of the 
proteasome inhibitor, MG132, c-Myc protein expression was rescued (Figure 15).  Cell 
proliferation (Figure 16A), glutamine uptake (Figure 16B)  and glutaminolytic protein 
expression (Figure 17) were partially rescued suggesting that troglitazone's inhibitory 
effect on glutaminolysis within the three cell lines is regulated, in part, through a 
proteasomal-mediated process.  To firmly establish a role for c-Myc in troglitazone's 
inhibitory effect on glutaminolysis, I used a lentiviral delivery system to overexpress c-
Myc in the H460 cell line (Figure 18A).  The c-Myc mutant, referred to as T58A c-Myc, 
codes for an alanine at the threonine 58 site thus rendering the c-Myc protein resistant to 
inhibitory phosphorylation at this residue (Gupta et al., 1993).  However, I was unable to 
rescue either cell proliferation (Figure 18B) or glutamine uptake (Figure 18C), suggesting 
that other potential mechanisms regulate c-Myc expression in response to troglitazone in 
these cell types.   
   The observation that certain types of tumor cells preferred glutamine as an 
energetic substrate over other amino acids and even glucose has been documented (Eagle 
et al., 1955, Reitzer et al., 1979).   Troglitazone treatment at concentrations of 40uM and 
80uM significantly inhibited steady-state ATP levels in all three cell lines (Figure 4).  
However, a limited inhibitory effect on glutamine uptake in the H460 cells at these same 
concentrations was evident (Figure 2) indicating that there are excess moles of ATP 
produced per mole of glutamine metabolized, or troglitazone treatment in the H460 cells 
may be causing a simultaneous inhibitory effect on another energy producing metabolic 
pathway such as the glycolytic pathway.   Previously, H460 cells have also been described  
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as possessing a glycolytic phenotype (Amoedo et al., 2011).  Interestingly, 40uM 
troglitazone treatment in the H460 cells resulted in an altered cellular morphology, 
changing the cells from a more rounded and clustered appearance to a sparser and more 
elongated appearance (data not shown),  demonstrating that the abrupt reduction in steady-
state ATP levels coincides with the cellular rearrangement of cytoskeleton proteins.  Other 
researchers using the H460 cell line have reported similar findings when cells were treated 
with the histone deacetylase (HDAC) inhibitor, sodium butyrate (Ameodo et al., 2011).  
Of note, troglitazone has been shown to inhibit HDAC activity in breast cancer cell lines 
leading to the inhibition of PI3/AKT signaling (Davies at al., 2010).   
            Troglitazone exerts effects through a PPAR-independent mechanism 
 Because troglitazone is a specific ligand for the nuclear hormone receptor PPARγ 
(Lehman et al., 1995), I needed to assess the possible role of PPARs in altering glutamine 
metabolism in our cell lines in response to troglitazone treatment.   For this purpose, I 
elected to use siRNAs directed against PPARα and PPARγ targets (Figure 7A-B).  
PPARα is known to regulate enzymes involved in amino acid metabolism such as the 
aminotransferases ALT and AST (Kersten et al., 2001) and troglitazone may bind to 
PPARα though with a greatly reduced affinity than PPARγ (Lehamn et al., 1995).  In 
addition, I utilized a potent irreversible PPARγ selective antagonist 2-chloro-5-
nitrobenzanilide (GW9662) at a concentration of 10uM, a concentration that is predicted 
to be sufficient to antagonize PPARα which displays a lesser affinity for the antagonist. 
(Leesnitzer et al., 2002).  The results obtained from these studies confirm that 
troglitazone's inhibitory effects on cell growth are not PPAR-dependent since knockdown 
of either PPARγ or PPARα concomitant with troglitazone  treatment was unable to rescue   
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 glutamine uptake (Figure 8, Figure 10) and cell proliferation  (Figure 9, Figure 11). 
Additional evidence for a PPAR-independent mechanism was obtained using the PPARγ 
antagonist, GW9662.  Again, treatment with troglitazone concomitant with GW9662 
treatment failed to result in the rescue of cell proliferation (Figure 13) or glutamine 
uptake (Figure 12) in any of the three cell lines.  
Troglitazone and metformin:  synergistic effect 
 Previously, researchers have shown that the drug metformin is able to sensitize 
tumor cells to glutamine withdrawal (Fendt et al., 2013). Troglitazone treatment coupled 
with metformin treatment resulted in a synergistic inhibitory effect on cell proliferation in 
two cell lines (Figure 19).  Cell proliferation at 48 hours and 72 hours with the 
combination drug treatment resulted in a synergistic inhibitory effect in the H460 cells.  
In addition, cell proliferation at 48 hours with the combination drug treatment also 
resulted in a synergistic inhibitory effect in the HeLa 229 cells.  Previous research using 
troglitazone in combination with other drugs such as lovestatin resulted in synergistic 
inhibition of proliferation in cancer cells with the researchers citing that the inhibition 
occurred as a result of E2F1 protein inhibition by lovestatin and p27 protein (cell cycle 
inhibitor) accumulation in response to troglitazone  (Yao et al., 2006)  While the clinical 
safety profile of co-administration of metformin and troglitazone is currently being 
examined within Type II diabetic patients, our data lends support to the combinatorial 
repurposing of these compounds as additional anti-tumor strategies.   
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SUMMARY AND CONCLUSIONS 
 The search for agents capable of modulating the metabolic phenotypes of tumor 
cells is a focus of cancer research.  Previously, FDA approved drugs for the treatment of 
Type II diabetes including the thiazolidinedione drug, troglitazone , have shown some 
promise in inhibiting  proliferation of tumor cells in vitro and in vivo (Galli et al., 2006, 
He et al., 2006, Kubota et al., 1998 ).    Furthermore, troglitazone has been shown to 
modulate glutaminolysis in certain cell lines ( Routh et al., 2002, Coates et al., 2002, 
Welborne et al., 2004, Turturro et al., 2004, Friday et al., 2011, Oliver et al., 2008, Oliver 
et al,. 2010).   Here, I reported that within glutamine -dependent transformed and tumor 
cell lines, including mouse embryonic fibroblasts depleted of RB pocket proteins (TKO 
MEF), human cervical adenocarcinoma cells (HeLa 229) and  human non-small cell lung 
carcinoma cells (H460),  troglitazone treatment  inhibits glutamine uptake, glutaminolytic 
protein expression,  steady-state ATP levels, and glutamine carbon flux into the TCA 
cycle, concomitantly with inhibiting proliferation.   Taken together, these results indicate 
an overall suppression of glutaminolysis and cell proliferation by troglitazone.  
  Knockdown of the expression of PPARγ or PPARα by siRNA species or 
inhibition of PPAR activation by PPARγ antagonist, GW9662, failed to restore glutamine 
uptake and cell proliferation in cells that were co-treated with troglitazone.   These results 
suggest that suppression of glutaminolysis and cell proliferation by troglitazone occurs 
through a PPAR-independent mechanism.   
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  Transcription factors other than PPARs have been shown to play a role in the 
regulation of glutaminolytic enzymes.  The transcription factor c-Myc is able to alter the 
cellular transcriptome and stimulate mitochondrial glutaminolysis,   ultimately leading to 
glutamine dependency (Yuneva et al., 2007, Wise et al., 2008).    The c-Myc protein has 
been shown to regulate the glutaminase (GLS1) protein expression through a post-
transcriptional mechanism (Gao et al., 2009).   Recently,  researchers demonstrated that 
c-Myc expression was inhibited in prostate cancer cell lines treated with troglitazone 
(Akinyeke et al. ,2011 ).  Results from this thesis project support Akinyeke's findings. 
Troglitazone treatment inhibited expression of c-Myc protein levels in a dose-dependent 
manner in three glutamine-dependent cell lines.   Treatment of the H460 cell line with a 
proteasomal inhibitor, MG132, in conjunction with troglitazone resulted in the rescue of 
the c-Myc protein and partial rescue of cell proliferation and glutamine uptake, indicating 
troglitazone's inhibitory effect on cell growth and c-Myc expression are proteosomal-
mediated.    However, overexpression of a T58A mutant c-Myc, which is resistant to 
phosphorylation that triggers proteasomal degradation, was unable to rescue cell 
proliferation and glutamine uptake in H460 cells that were treated with troglitazone, 
suggesting that additional layers of regulation affect c-Myc stability in these cells.  
 The potential for drug synergy encourages the clinical use of drug combinations 
for the treatment of many diseases, including cancer.  Metformin, a biguanide drug used 
for the treatment of Type II diabetes which gained FDA approval for use in the U.S.A. in 
1995 (Wysowski et al., 2003) has shown promise as an anti-tumorigenic agent (Kourelis 
et al., 2012).    Furthermore, metformin has been shown to sensitize cancer cells to 
glutamine disruption (Fendt et al., 2013).  Using the glutamine-dependent cell lines, I   
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observed a synergistic inhibitory effect on cell proliferation with combined treatment of 
10uM troglitazone and 1mM metformin, thus providing evidence for the possible 
repurposing of these agents, especially in combination with other targeted treatment 
strategies. 
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